NEW PRODUCTS
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 20576 | STX-721 | 2765525-82-2 | ≧98.0% |  |
| STX-721 is a next-generation, orally delivered therapy, designed with potential best- | ||||
| 20639 | SOP1812 (QN-302) | 2546091-70-5 | ≧98.0% | _2546091-70-5.png) |
| QN-302 is a G-quadruplex (G4)-selective transcription inhibitor. | ||||
| 20640 | FLAG-003 | 1614235-14-1 | ≧98.0% |  |
| FLAG-003 is a multi-acting, water-soluable small molecule therapeutic designed to tar | ||||
| 20641 | KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) | 2082765-42-0 | ≧98.0% |  |
| KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) is a small molecule inhibitor of protein | ||||
| 20642 | OATD-02 | 2146132-73-0 | ≧98.0% |  |
| OATD-02, an orally available dual arginase inhibitor (ARG1 and ARG2), is in phase I c | ||||
| 262401 | MRTX1719 | 2630904-45-7 | ≧96.0% | |
| MRTX1719 is a potent and selective binder to the PRMT5•MTA complex and selectively | ||||
| 24004 | T-1095 | 209746-59-8 | ≧96.0% |  |
| T-1095 is a potent and selective inhibitor of Na+-glucose cotransporters (SGLTs). | ||||
| 24008 | RNK-05047 | 2503036-46-0 | ≧98.0% |  |
| RNK-05047 is a PROTAC degrader of BRD4 which displays significant tumor growth inhibi | ||||
| 24009 | Asengeprast (FT011) | 1001288-58-9 | ≧98.0% |  |
| Asengeprast (FT011) is an anti-fibrotic agent thatreduces mRNA expression of collagen | ||||
| 24010 | Zasocitinib | 2272904-53-5 | ≧98.0% |  |
| Zasocitinib is under development for the treatment of moderate to severe plaque psori | ||||
| 24011 | Zongertinib | 2728667-27-2 | ≧98.0% |  |
| Zongertinib [BI 1810631] is a human epidermal growth factor receptor 2 (HER2) inhibit | ||||
| 24012 | Zunsemetinib | 1640282-42-3 | ≧98.0% |  |
| Zunsemetinib is an investigational oral mitogen-activated protein kinase-activated pr | ||||